Shire touts $10B sales target to fend off AbbVie as other suitors circle
23.06.2014 / Fierce Pharma
Shire has maintained that it's better off alone, rejecting three recent merger bids from AbbVie worth as much as $46.5 billion. Now, it's laying out its case. The Irish drugmaker outlined a plan to double sales by 2020–but that may not be enough to keep predators at bay.